Cullinan Therapeutics (CGEM) Net Income towards Common Stockholders (2021 - 2023)
Historic Net Income towards Common Stockholders for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$25.6 million.
- Cullinan Therapeutics' Net Income towards Common Stockholders rose 555.66% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 24197.15%. This contributed to the annual value of -$167.6 million for FY2024, which is 804.25% down from last year.
- According to the latest figures from Q4 2023, Cullinan Therapeutics' Net Income towards Common Stockholders is -$25.6 million, which was up 555.66% from -$39.2 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Net Income towards Common Stockholders registered a high of $174.1 million during Q2 2022, and its lowest value of -$58.1 million during Q1 2023.
- For the 3-year period, Cullinan Therapeutics' Net Income towards Common Stockholders averaged around -$9.4 million, with its median value being -$25.2 million (2022).
- Examining YoY changes over the last 5 years, Cullinan Therapeutics' Net Income towards Common Stockholders showed a top increase of 115885.39% in 2022 and a maximum decrease of 100627.2% in 2022.
- Quarter analysis of 3 years shows Cullinan Therapeutics' Net Income towards Common Stockholders stood at -$34.2 million in 2021, then rose by 20.87% to -$27.1 million in 2022, then increased by 5.56% to -$25.6 million in 2023.
- Its last three reported values are -$25.6 million in Q4 2023, -$39.2 million for Q3 2023, and -$32.2 million during Q2 2023.